Robinhood To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.

Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.

European Commission Approves Acadia’s DAYBU For Rett Syndrome Patients Aged Five And Older Following Successful Phase 3 LAVENDER Study

CARMAX, INC. (NYSE: KMX) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.

CALIX, INC. (NYSE: CALX) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Calix, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation focuses on shareholders who purchased shares before January 28, 2026.